Henkel closed the acquisition of epiCS Skin Model Technology from SkinInVitro GmbH, located in Troisdorf, Germany.
WHO: Under its brand Phenion, Henkel provides biotechnologically constructed skin models to interested contract research organizations and research institutes. With the Phenion skin models, the company offers alternative in vitro test systems which can be used not only for basic research in dermatology and cosmetic sciences but also for the safety assessment of raw materials and finished products.
IN THEIR OWN WORDS: “With this acquisition, we are strengthening our existing product portfolio in the field of reconstructed human tissue models,” explains Dr. Dirk Petersohn, responsible for the Phenion brand at Henkel Beauty Care. “With the epiCS technology, we can now offer our clients tissue models which are well-suited and regulatory accepted for analyzing the skin-corrosive and irritating potential of substances. Hence, this reasonable complement of our already existing product portfolio gives us the opportunity to serve our customers even better. We are looking forward to integrating the SkinInVitro team in order to expedite together the development and distribution of alternative test methods.”
“I am pleased that our more than 20 years of experience in technology development will be continued at Henkel,” says Horst W. Fuchs, founder and owner of SkinInVitro GmbH. “It is a unique chance for the team to become an integral part of the globally acting Henkel company and to integrate its expertise in respect of the epiCS technology.”
DETAILS:
